BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fernández-salazar L, Muñoz F, Barrio J, Muñoz C, Pajares R, Rivero M, Prieto V, Legido J, Bouhmidi A, Herranz M, Fernández N, Sánchez-ocaña R, Joao D, Santos F. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study). Scandinavian Journal of Gastroenterology 2015;51:186-95. [DOI: 10.3109/00365521.2015.1070900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Macaluso FS, Cavallaro F, Felice C, Mazza M, Armuzzi A, Gionchetti P, Vecchi M, Orlando A. Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. Dig Liver Dis 2019;51:613-20. [PMID: 30826279 DOI: 10.1016/j.dld.2019.01.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis 2018;12:635-43. [PMID: 29370397 DOI: 10.1093/ecco-jcc/jjy004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 11.8] [Reference Citation Analysis]